Invitation Meeting & Conference Call for Clavis Pharma's new $205 million deal with Clovis Oncology for the development & commercialisation of anti-cancer agent CP-4126 in Asia and RoW
(Thomson Reuters ONE) -
Oslo, Norway, 11 November 2010
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug discovery and
development company, and Clovis Oncology, Inc., announced today a new agreement
for the further development and commercialisation of CP-4126 (also known as CO-
101), which is currently in Phase II development in pancreatic cancer. CP-4126
is a novel, patented, lipid-conjugated form of the anti-cancer drug gemcitabine
that has the potential to improve treatment outcomes in a large subset of
patients with pancreatic cancer and certain other solid tumours.
Oslo Meeting - 10:00am CET
A meeting for investors, analysts and press will take place in Oslo at 10.00 CET
today, 11 November 2010 at Thon Conference Vika Atrium, Munkedamsveien 45, Oslo,
Norway.
International Conference Call - 12:00pm CET
An international conference call will take place at 12:00 CET - details are
given below.
Access the audio for the meeting by dialling the following and quoting:
Confirmation Code 3869864
Participant Telephone numbers:
+47 24 15 97 57 Norway/International Toll
+44 (0)20 7138 0845 UK Toll
+1 212 444 0896 USA Toll
For visuals click on the direct access link:
http://www.livemeeting.com/cc/premconfeurope/join?id=4956336&role=attend&pw=pw66
23
Participating in the Meeting and Conference Call will be:
Olav Hellebø, CEO, Clavis Pharma ASA
Patrick Mahaffy, President & CEO, Clovis Oncology Inc.
The presentation will be made available on www.clavispharma.com in the Investors
section from 10:00 CET. A webcast replay of the conference call will be
available from Clavis Pharma's website, www.clavispharma.comfor a period of 30
days.
Contact:
Olav Hellebø, CEO
Office: +47 24 11 09 65 / Mobile: +44 783 390 4901
E-mail:olav.hellebo(at)clavispharma.com
Gunnar Manum, CFO
Office: +47 24 11 09 71/ Mobile: +47 95 17 91 90
E-mail:gunnar.manum(at)clavispharma.com
For international press enquiries:
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
Office: +44 207 282 2948
E-mail:clavispharma(at)citigatedr.co.uk
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1461225]
Invitation Meeting and Conference call:
http://hugin.info/136972/R/1461225/400472.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Clavis Pharma ASA via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 11.11.2010 - 07:02 Uhr
Sprache: Deutsch
News-ID 48646
Anzahl Zeichen: 3270
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Invitation Meeting & Conference Call for Clavis Pharma's new $205 million deal with Clovis Oncology for the development & commercialisation of anti-cancer agent CP-4126 in Asia and RoW"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
